Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Astrazeneca Plc ADR
(NQ:
AZN
)
75.17
+0.14 (+0.19%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Astrazeneca Plc ADR
< Previous
1
2
3
4
5
6
7
8
9
...
52
53
Next >
AstraZeneca Joins Anti-Obesity Race Dominated By Eli Lilly And Novo Nordisk, Reports Mixed Q3 Earnings
November 09, 2023
AstraZeneca Plc (NASDAQ: AZN) has reported Q3 FY23 core EPS of $1.73, u
Via
Benzinga
Wall Street To Snap Longest Winning Streak Since 2021 Today? Earnings, Bond Yields In Focus Ahead Of Powell's Speech
November 09, 2023
The stock market’s momentum appears to be waning, and futures suggest a mixed opening for Thursday. Earnings reports have generally been positive, with companies like Walt Disney Co.
Via
Benzinga
Earnings Review: AstraZeneca Increases Profit Outlook, Reports 17% EPS Growth
November 09, 2023
AstraZeneca reported an EPS of $1.73 for Q3 2023 and $5.8 for 9M 2023.
Via
Talk Markets
IMFINZI® (durvalumab) plus bevacizumab met primary endpoint for progression-free survival in liver cancer eligible for embolization in EMERALD-1 Phase III trial
November 09, 2023
From
AstraZeneca
Via
Business Wire
Price Over Earnings Overview: AstraZeneca
November 06, 2023
Via
Benzinga
Comparative Study: AstraZeneca And Industry Competitors In Pharmaceuticals Industry
October 30, 2023
Via
Benzinga
AstraZeneca to leverage its global industrial-scale manufacturing and digital capabilities to boost US renewable natural gas productivity
November 08, 2023
From
AstraZeneca
Via
Business Wire
BioMarin Surges As Activist Investor Elliott Reportedly Builds $1 Billion Stake
November 07, 2023
The company's recently FDA-approved gene therapy is struggling to gain traction.
Via
Investor's Business Daily
NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) Evaluating Impact of Exclusive Drug-Delivery Solution on GLP-1 Drugs
November 03, 2023
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Zibotentan/dapagliflozin combination demonstrated significant albuminuria reduction in patients with chronic kidney disease and proteinuria in ZENITH-CKD Phase IIb trial
November 03, 2023
From
AstraZeneca
Via
Business Wire
7 Evergreen Stocks for Long-term Wealth Generation
November 03, 2023
These are the stocks to buy for long-term wealth as they represent companies that will continue to grow and boost shareholder returns.
Via
InvestorPlace
Why Is Cancer Player Cellectis Stock Trading Over 100% Higher Today?
November 01, 2023
Cellectis SA (NASDAQ: CLLS) shares are trading higher after the company
Via
Benzinga
Why Is Cellectis (CLLS) Stock Up 175% Today?
November 01, 2023
Cellectis stock is taking off on Wednesday as investors in CLLS react to a massive $245 million investment from AstraZeneca.
Via
InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
November 01, 2023
We're starting off Wednesday with a breakdown of the biggest pre-market stock movers investors will want to keep track of today!
Via
InvestorPlace
Can Diabetes, Weight-Loss Drugs Get Even Better?
October 30, 2023
Via
Investor Brand Network
Can Diabetes, Weight-Loss Drugs Get Even Better?
October 30, 2023
EQNX::TICKER_START (NASDAQ:LEXX,NYSE:NVO:NYSE:PFE,NYSE:MRK,NASDAQ:AZN) EQNX::TICKER_END
Via
FinancialNewsMedia
3 No-Brainer Stocks to Buy for Under $100 Right Now
October 28, 2023
A couple of these stocks might not be available for under $100 for too much longer.
Via
The Motley Fool
Why Is LumiraDx (LMDX) Stock Down 35% Today?
October 24, 2023
LumiraDx stock is falling on Tuesday as shares of LMDX stock give up some of the gains they saw on Monday after announcing a partnership.
Via
InvestorPlace
US Food and Drug Administration accepts for review AstraZeneca’s Supplemental Biologics License Application for self-administration of FLUMIST® QUADRIVALENT (Influenza Vaccine Live, Intranasal)
October 24, 2023
From
AstraZeneca
Via
Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
October 23, 2023
Via
Benzinga
Datopotamab deruxtecan improved progression-free survival vs. chemotherapy in patients with previously treated non-small cell lung cancer in TROPION-Lung01 Phase III trial
October 23, 2023
From
AstraZeneca
Via
Business Wire
ENHERTU® (fam-trastuzumab deruxtecan-nxki) Demonstrated Clinically Meaningful Survival Across Multiple HER2-Expressing Advanced Solid Tumors in DESTINY-PanTumor02 Phase II Trial
October 23, 2023
From
AstraZeneca
Via
Business Wire
Datopotamab deruxtecan significantly extended progression-free survival vs. chemotherapy in patients with HR-positive, HER2-low or negative breast cancer in TROPION-Breast01 Phase III trial
October 23, 2023
From
AstraZeneca
Via
Business Wire
Why Is LumiraDx (LMDX) Stock Up 323% Today?
October 23, 2023
LumiraDx stock is rising higher on Monday with heavy trading of LMDX shares after announcing a partnership with AstraZeneca.
Via
InvestorPlace
Datopotamab deruxtecan plus IMFINZI® (durvalumab) demonstrated robust and durable tumor responses in 1st-line treatment of patients with metastatic triple-negative breast cancer in BEGONIA Phase Ib/II trial
October 22, 2023
From
AstraZeneca
Via
Business Wire
IMFINZI® (durvalumab) plus LYNPARZA® (olaparib) reduced the risk of disease progression or death by 45% vs. chemotherapy in advanced or recurrent endometrial cancer
October 21, 2023
From
AstraZeneca
Via
Business Wire
TAGRISSO® (osimertinib) plus chemotherapy reduced the risk of disease progression in the brain by 42% in patients with EGFR-mutated advanced lung cancer and brain metastases at baseline
October 21, 2023
From
AstraZeneca
Via
Business Wire
Stock Market Struggles As Treasury Yields Soar; Tesla, Nvidia Among Notable Losers: Weekly Review
October 20, 2023
The major indexes saw significant loses as Treasury yields soared.
Via
Investor's Business Daily
Merck Signs Multi-Billion Deal With Japan's Daiichi Sankyo For Cancer Therapy Drug Development
October 20, 2023
Merck & Company, Inc. (NYSE: MRK) and Japan's Daiichi Sankyo Co. Ltd. (OTC: DSKYF) entered into a global development and commercialization agreement.
Via
Benzinga
IMFINZI® (durvalumab) plus chemotherapy more than doubled pathologic complete response rate in resectable early-stage gastric and gastroesophageal junction cancers versus chemotherapy alone
October 20, 2023
From
AstraZeneca
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
52
53
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.